Etanercept in the treatment of vitiligo.
Rigopoulos
Dimitris
D
Gregoriou
Stamatis
S
Larios
George
G
Moustou
Evi
E
Belayeva-Karatza
Elena
E
Kalogeromitros
Dimitris
D
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000068800:Etanercept; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D008297:Male; D010865:Pilot Projects; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014820:Vitiligo / Q000175:diagnosis* / Q000188:drug therapy*
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept